$SSII SS Innovations Welcomes “Father of Surgica
Post# of 35445
(Total Views: 59)
Posted On: 09/10/2024 9:52:27 AM
$SSII SS Innovations Welcomes “Father of Surgical Robotics” Dr. Fredric Moll to Board
https://www.globenewswire.com/en/news-release...Board.html
FORT LAUDERDALE, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, is pleased to announce the addition of Dr. Fredric Moll to its Board of Directors, where he will serve as Vice Chairman. Dr. Moll is the founder of Intuitive Surgical and is widely regarded as the “father of surgical robotics.”
Dr. Moll brings a wealth of industry experience and expertise to the board: He oversaw the development and commercialization of the da Vinci surgical robotic system. He most recently served as Chief Development Officer for Johnson & Johnson Medical Devices Companies from April 2019 to March 2023. Dr. Moll was a co-founder, Chairman and Chief Executive Officer of Auris Health, Inc., a robotics medical device company that was acquired by Johnson & Johnson in 2019. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. He served on the board of Shockwave Medical, Inc. from March 2011 through its acquisition by Johnson & Johnson in May 2024. Dr. Moll was an early investor in Avra Medical Robotics and is a current investor in SS Innovations.
“The strength and caliber of Dr. Moll’s leadership is peerless, and he will be a tremendous addition to our Board of Directors,” said Dr. Sudhir Srivastava, SS Innovations Chairman and CEO . “Joining us during the most robust phase of global growth to date, his appointment is perfectly timed. As a pioneer in robotic surgery, Dr. Moll offers a unique perspective and legacy as well as superior insight on the direction and promising future of the industry and SS Innovations.”
Dr. Moll added, “I am excited to help with SS Innovation’s mission to bring the benefits of robotic surgery not just to more people in the United States but also to the rest of the world. This technology should be available to everyone on the planet, and I believe the Company successfully addresses the reasons why others have not yet been able to do so. It is much more affordable than what is out there now without sacrificing any clinical capabilities. It even has capabilities such as in cardiac that no one else even has. I also believe that the system’s proven telesurgery capabilities as well as its related teaching and proctoring tools will prove invaluable.”
Earlier this year, SS Innovations launched the SSI Mantra 3, the newest and most advanced version of its surgical robotic system that makes possible more affordable and accessible surgical care across the globe.
The SSi Mantra 3 provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more while engaging with surgeons and surgical teams to improve safety and efficiency during procedures. The regulatory approval process from the U.S. Food and Drug Administration (FDA) is already underway, and SS Innovations anticipates receiving approval to market in the latter part 2025.
https://www.globenewswire.com/en/news-release...Board.html
FORT LAUDERDALE, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, is pleased to announce the addition of Dr. Fredric Moll to its Board of Directors, where he will serve as Vice Chairman. Dr. Moll is the founder of Intuitive Surgical and is widely regarded as the “father of surgical robotics.”
Dr. Moll brings a wealth of industry experience and expertise to the board: He oversaw the development and commercialization of the da Vinci surgical robotic system. He most recently served as Chief Development Officer for Johnson & Johnson Medical Devices Companies from April 2019 to March 2023. Dr. Moll was a co-founder, Chairman and Chief Executive Officer of Auris Health, Inc., a robotics medical device company that was acquired by Johnson & Johnson in 2019. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. He served on the board of Shockwave Medical, Inc. from March 2011 through its acquisition by Johnson & Johnson in May 2024. Dr. Moll was an early investor in Avra Medical Robotics and is a current investor in SS Innovations.
“The strength and caliber of Dr. Moll’s leadership is peerless, and he will be a tremendous addition to our Board of Directors,” said Dr. Sudhir Srivastava, SS Innovations Chairman and CEO . “Joining us during the most robust phase of global growth to date, his appointment is perfectly timed. As a pioneer in robotic surgery, Dr. Moll offers a unique perspective and legacy as well as superior insight on the direction and promising future of the industry and SS Innovations.”
Dr. Moll added, “I am excited to help with SS Innovation’s mission to bring the benefits of robotic surgery not just to more people in the United States but also to the rest of the world. This technology should be available to everyone on the planet, and I believe the Company successfully addresses the reasons why others have not yet been able to do so. It is much more affordable than what is out there now without sacrificing any clinical capabilities. It even has capabilities such as in cardiac that no one else even has. I also believe that the system’s proven telesurgery capabilities as well as its related teaching and proctoring tools will prove invaluable.”
Earlier this year, SS Innovations launched the SSI Mantra 3, the newest and most advanced version of its surgical robotic system that makes possible more affordable and accessible surgical care across the globe.
The SSi Mantra 3 provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more while engaging with surgeons and surgical teams to improve safety and efficiency during procedures. The regulatory approval process from the U.S. Food and Drug Administration (FDA) is already underway, and SS Innovations anticipates receiving approval to market in the latter part 2025.
(0)
(0)Scroll down for more posts ▼